Irinotecan for Lung Cancer: 12 Real Stories

12 stories match lung cancer and irinotecan. 10 of them mention cisplatin.

Cancer Stories

A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Extensive-stage small cell lung cancer: multi-line treatment complicated by glucocorticoid-refractory immune-related cystitis

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported for SCLC. Bladder biopsy during cystitis showed mostly CD3/CD8-positive T-cell inflammation.

As of December 2025, the cancer had progressed through multiple systemic lines, new brain metastasis had appeared, and care had shifted to palliative symptomatic treatment; immune-related cystitis had resolved after prednisone plus mycophenolate mofetil.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Extensive-stage small cell lung cancer with brain and adrenal progression after prolonged disease control

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Small-cell lung cancer markers included CD56, CgA and TTF-1; Ki-67 was 80%.

Metastatic Site: brain, right adrenal gland, left adrenal gland

After 31 months of stability on second-line anlotinib with palliative chemoradiotherapy, disease progressed in July 2024 with new brain lesions and adrenal progression; the patient declined additional systemic options and continued anlotinib.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Metastatic NSCLC with ATM mutations: 28-month response to olaparib before progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: cfDNA showed ATM and ATM mutations. Common NSCLC drivers were negative; initial tumor markers were negative.

Metastatic Site: liver, left pubic bone, bilateral pulmonary nodules,…

After 28 months of remission and improved quality of life on olaparib, June 2024 PET-CT showed progression with a new 1.2 cm hypermetabolic left lower-lobe pulmonary nodule; olaparib was still being continued at the October 2024 clinic visit.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

EGFR-Mutant Lung Adenocarcinoma That Transformed to Small Cell Lung Cancer

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain, adrenal gland, liver, thyroid

The cancer progressed after small-cell transformation with adrenal, thyroid, liver and brain involvement, and she died 52.7 months after the original diagnosis from disease progression and organ failure.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

ALK-Fusion Small Cell Lung Cancer Responding to ALK-Targeted Therapy

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EML4-ALK fusion

Metastatic Site: brain

After several earlier treatments stopped controlling the cancer, ALK-targeted iruplinalkib produced a partial response and was still controlling disease after more than 8 months.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Small Cell Lung Cancer With Paraneoplastic Cushing Syndrome Treated With Immunochemotherapy

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 negative; low tumor mutation burden; microsatellite stable

Metastatic Site: liver, abdominal wall, left ilium

He lived 20 months after diagnosis. After repeated treatment responses and later progression, he died in September 2023 from respiratory and cardiac failure during a severe infection following treatment-related myelosuppression.

PubMed Central
OutcomeIn Memory
SH
Lung Cancer

Severe headache during chemotherapy for small-cell lung cancer

Patient Info: Anonymized, Male, 50s

After the regimen change, he completed five chemotherapy cycles, remained free of severe headache, and had improvement in chest pain, cough, and breathing.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

More than 10 years living with relapsing extensive-stage small cell lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Chromogranin-positive.

Metastatic Site: pleura; pancreas; left kidney and perinephric region

After five treatment lines and several metastatic relapses over more than 10 years, his latest irinotecan and carboplatin course produced another partial response and he was doing well at the last follow-up.

PubMed Central
OutcomeResponding Well